Tag: David Amess

The below Parliamentary question was asked by David Amess on 2016-02-03.

To ask the Secretary of State for Health, what recent discussions he has had with Public Health England on steps to increase cervical screening uptake among women from disadvantaged backgrounds.

Jane Ellison

NHS England closely monitors the coverage rates for cervical screening in all age groups and is committed to improving coverage and reducing variation between all groups including black and minority ethnic women, women with learning disabilities and women from disadvantaged backgrounds.

Local NHS England commissioners analyse coverage rates within their area and work with general practices to improve coverage by sharing best practice. For example, commissioners in London have developed a screening coverage strategy and delivery plan, including:

― Increased public awareness and engagement with screening programmes across all communities;

― increased engagement with primary care and improved reliability of data; and

― working with screening providers to optimise coverage.

In addition to this:

― A primary care cancer screening best practice guide has been developed jointly with the transforming cancer services team, clinical commissioning groups and local authority public health representatives;

― linking with Cancer Research UK facilitators and Macmillan Cancer Support general practitioners to support best practice for screening in general practice; and

― imperial College is conducting a randomised controlled trial to assess the effectiveness of texting non-responders on improving coverage.

NHS England is working in partnership with Cancer Research UK and Macmillan Cancer Support on the ACE (Accelerate, Coordinate, Evaluate) Programme aiming to generate knowledge about effective approaches to achieve earlier diagnosis. A number of ACE test sites are evaluating approaches to increase screening rates in a range of groups, including black and ethnic minority women, women with learning disabilities and women from disadvantaged backgrounds.

To explore the potential to increase rates of cervical screening in young women, the National Institute for Health Research (NIHR) Health Technology Assessment programme has commissioned a £1 million study to determine which interventions are effective at increasing screening uptake amongst women aged 25 who are receiving their first invitation from the NHS Cervical Screening Programme. The study began in November 2011 and reports can be expected later in 2016.

In addition, the Department of Health Behavioural Insight team has undertaken a trial to investigate the use of behavioural insights to optimise the content of the invitation letter for cervical screening. Results are due in summer 2016.

A routine human papillomavirus vaccination programme has been available in England since 2008, and offers immunisation to girls aged 12-14 years. It is expected that the vaccine will reduce the already low rates of cervical cancer in these young women and allow them to be protected for years to come.

The below Parliamentary question was asked by David Amess on 2016-03-03.

To ask the Secretary of State for Health, with reference to the oral contribution of the Lord Patel of 24 February 2015, column 882HL, if he will place in the Library a copy of all correspondence from September 2014 between the expert panel convened by the Human Fertilisation and Embryology Authority and Professor Grifo.

Jane Ellison

The correspondence referred to is a personal email exchange between one expert panel member and Professor Grifo, following the third scientific review of the safety and efficacy of methods to avoid mitochondrial disease in 2014. It would not be appropriate for a copy of this private correspondence to be placed in the Library.

The below Parliamentary question was asked by David Amess on 2016-05-09.

To ask the Secretary of State for Work and Pensions, what proportion of the Health and Work Innovation Fund his Department plans to allocate to programmes for people with arthritis.

Justin Tomlinson

At the spending review, the Work and Health Unit secured £115m of funding, including at least £40m for a Work and Health innovation fund.

The Work and Health Innovation Fund will trial new ways to help working age disabled people and people with health conditions get in, stay in, and return to work as well as benefit from improved health outcomes. This will include support for people with musculoskeletal conditions, including arthritis.

The below Parliamentary question was asked by David Amess on 2016-07-20.

To ask the Secretary of State for Health, whether everyone who was registered with Skipton and received the £20,000 lump sum payment will be automatically entitled to the new annual payments.

Nicola Blackwood

The reformed scheme will provide a payment to all those with hepatitis C, even if they have been treated, for the current spending review period. A review of the scheme will take place towards the end of this spending review period.

All those who are currently bereaved partners/spouses and all those who will be bereaved partner/spouses in future will receive a £10,000 lump sum payment and will have continued access to discretionary support. Discretionary support will continue to be available to the bereaved, as well as to infected individuals.

All infected individuals who are registered with Skipton as having hepatitis C stage 1 (nearly 2,500 people) will be eligible for the new stage 1 annual payment.

The below Parliamentary question was asked by David Amess on 2015-10-29.

To ask the Secretary of State for Health, what assessment he has made of the suitability of individual funding requests for preventive treatments and the criteria to demonstrate exceptional clinical circumstances in relation to such requests.

George Freeman

NHS England has advised that if there is a commissioning policy in place for a treatment, and the patient fulfils the treatment criteria contained within this, then an individual funding request (IFR) is not required, as the treatment will be routinely funded. It is only if the patient’s treatment falls outside of the criteria that an IFR would be appropriate or if there is no policy in place for the treatment/indication.

Neither the Department nor NHS England has made any assessment of the suitability of IFRs for preventative treatments.

The below Parliamentary question was asked by David Amess on 2015-11-30.

To ask the Secretary of State for Environment, Food and Rural Affairs, what recent progress has been made in (a) reviewing the effectiveness of her Department’s Code of Practice on the use of snares and (b) improving operator compliance with that Code.

Rory Stewart

In 2012 Defra published research on the extent of use and humaneness of snares in England and Wales. Following publication of the report, officials worked with stakeholders to explore options to improve the humaneness of snaring. Ministers are currently considering these options, including the issue of improved guidance on snaring.

The below Parliamentary question was asked by David Amess on 2016-01-07.

To ask the Secretary of State for Health, how many highly specialised technologies are currently being assessed by the NHS England highly specialised technologies assessment process.

George Freeman

NHS England is currently developing a refined process for the prioritisation of proposed new investments in specialised services and highly specialised services.

The number of technologies to be routinely commissioned by NHS England will be determined by the new process.

The below Parliamentary question was asked by David Amess on 2016-02-03.

To ask the Secretary of State for Health, what steps his Department is taking to reduce levels of cervical cancer in 25 to 29 year olds.

Jane Ellison

NHS England closely monitors the coverage rates for cervical screening in all age groups and is committed to improving coverage and reducing variation between all groups including black and minority ethnic women, women with learning disabilities and women from disadvantaged backgrounds.

Local NHS England commissioners analyse coverage rates within their area and work with general practices to improve coverage by sharing best practice. For example, commissioners in London have developed a screening coverage strategy and delivery plan, including:

― Increased public awareness and engagement with screening programmes across all communities;

― increased engagement with primary care and improved reliability of data; and

― working with screening providers to optimise coverage.

In addition to this:

― A primary care cancer screening best practice guide has been developed jointly with the transforming cancer services team, clinical commissioning groups and local authority public health representatives;

― linking with Cancer Research UK facilitators and Macmillan Cancer Support general practitioners to support best practice for screening in general practice; and

― imperial College is conducting a randomised controlled trial to assess the effectiveness of texting non-responders on improving coverage.

NHS England is working in partnership with Cancer Research UK and Macmillan Cancer Support on the ACE (Accelerate, Coordinate, Evaluate) Programme aiming to generate knowledge about effective approaches to achieve earlier diagnosis. A number of ACE test sites are evaluating approaches to increase screening rates in a range of groups, including black and ethnic minority women, women with learning disabilities and women from disadvantaged backgrounds.

To explore the potential to increase rates of cervical screening in young women, the National Institute for Health Research (NIHR) Health Technology Assessment programme has commissioned a £1 million study to determine which interventions are effective at increasing screening uptake amongst women aged 25 who are receiving their first invitation from the NHS Cervical Screening Programme. The study began in November 2011 and reports can be expected later in 2016.

In addition, the Department of Health Behavioural Insight team has undertaken a trial to investigate the use of behavioural insights to optimise the content of the invitation letter for cervical screening. Results are due in summer 2016.

A routine human papillomavirus vaccination programme has been available in England since 2008, and offers immunisation to girls aged 12-14 years. It is expected that the vaccine will reduce the already low rates of cervical cancer in these young women and allow them to be protected for years to come.

The below Parliamentary question was asked by David Amess on 2016-03-14.

To ask the Secretary of State for Health, with reference to the findings of the First Annual Report of the National Clinical Audit for Rheumatoid and Early Inflammatory Arthritis, published on 22 January 2016, on the proportion of patients in England and Wales referred within three working days of their GP appointment, what steps he is taking to improve the referral rate from GPs when inflammatory arthritis is suspected.

Jane Ellison

National Clinical Audits are commissioned and managed on behalf of NHS England by the Healthcare Quality Improvement Partnership (HQIP). Audits help drive improvement by providing local trusts with individual benchmarked reports on their performance against a range of measures, feeding back comparative findings to help participants identify necessary improvements for patients

The first annual report of the national clinical audit of rheumatoid and early inflammatory arthritis was published on 22 January 2016. The report identifies that although most services offer prompt educational support and agree targets for treatment with their patients, performance against criteria for referral and assessment could be improved. Since the audit, HQIP has reported that a number of trusts have successfully reconfigured their services in order to improve patient care. More information can be found at the following link:

www.hqip.org.uk/national-programmes/a-z-of-nca/arthritis-rheumatoid-and-early-inflammatory

To help clinicians to identify the symptoms of rheumatoid arthritis (RA) and make prompt referrals to specialists, the National Institute for Health and Care Excellence (NICE) published Rheumatoid arthritis: The management of rheumatoid arthritis in adults, in 2009. This best practice guideline sets out the signs and symptoms of the disease and emphasises the need for early diagnosis with urgent referral to a specialist rheumatologist on suspicion of RA. For those diagnosed with the condition, the guidance also recommends they should be offered the opportunity to take part in educational activities, including self-management programmes.

The NICE RA quality standard (QS), published in 2013, is based on the NICE guideline, and one of the seven quality statements recommends that people with suspected RA are assessed in a rheumatology service within three weeks of referral. However, whilst providers and commissioners must have regard to these standards in planning and delivering services, they do not provide a comprehensive service specification and are not mandatory.

Regarding the establishment of early arthritis clinics, the configuration of services, including decisions to such arthritis clinics, is a matter for the local National Health Service.

The latest monthly workforce statistics published by the Health and Social Care Information Centre showed that, as of November 2015, there were 563 full time equivalent rheumatology consultants employed in the NHS. This is an increase of 119 (26.8%) since May 2010. The recruitment and retention of staff is matter for local NHS services.

The below Parliamentary question was asked by David Amess on 2016-05-09.

To ask the Secretary of State for Work and Pensions, what proportion of Access to Work funding supports people with arthritis.

Justin Tomlinson

Access to Work does not record arthritis as a separate primary medical condition.

Access to Work statistics, which include a breakdown of numbers helped by primary medical condition, are published quarterly here:

https://www.gov.uk/government/collections/access-to-work-statistics-on-recipients–2’

“